Just weeks after receiving a €1.6-million grant from the Food and Drug Administration (FDA), biopharmaceutical firm Ability Pharma has closed a €2-million round of investment through the Capital Cell platform.The funds will go towards the company's Phase II clinical trial on its molecule ABTL0812 to treat pancreatic cancer.

Ability has received approval from the FDA and the Spanish Agency of Medicines and Medical Devices (AEMPS) to begin the clinical trial in Spain and the United States. 

It is an international multi-centre double-blind placebo-controlled trial in patients with pancreatic cancer, who will be treated with ABTL0812 and Folfirinox chemotherapy. In Spain, the study will be carried out at the Vall d’Hebron University Hospital in Barcelona, the Germans Trias i Pujol University Hospital in Badalona and the Dr. Josep Trueta University Hospital in Girona.

The company, member of CataloniaBio & HealthTech, plans to expand the study to France and Israel.

We recommend the article El gran salto de una ‘biotech’ catalana para curar el cáncer de páncreas by Àlex Font, journalist of Diari Ara.

Photo: Carles Domènech, executive president and CSO of Ability - © Ability Pharma.

You may also be interested in:

• Ability receives €1.6 million from FDA and opens round on Capital Cell
• Ability Pharma raises €5 million through Horizon EIC Accelerator programme